
Crinetics Pharmaceuticals, Inc. – NASDAQ:CRNX
Crinetics Pharmaceuticals stock price today
Crinetics Pharmaceuticals stock price monthly change
Crinetics Pharmaceuticals stock price quarterly change
Crinetics Pharmaceuticals stock price yearly change
Crinetics Pharmaceuticals key metrics
Market Cap | 4.90B |
Enterprise value | N/A |
P/E | -5.05 |
EV/Sales | -6.29 |
EV/EBITDA | 0.18 |
Price/Sales | 0.17 |
Price/Book | N/A |
PEG ratio | 0.40 |
EPS | -3.78 |
Revenue | N/A |
EBITDA | -247.78M |
Income | -235.46M |
Revenue Q/Q | -76.11% |
Revenue Y/Y | -53.93% |
Profit margin | -3460.38% |
Oper. margin | -3544.06% |
Gross margin | 0% |
EBIT margin | -3544.06% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCrinetics Pharmaceuticals stock price history
Crinetics Pharmaceuticals stock forecast
Crinetics Pharmaceuticals financial statements
Jun 2023 | 988K | -50.97M | -5159.82% |
---|---|---|---|
Sep 2023 | 346K | -57.45M | -16606.36% |
Dec 2023 | 0 | -60.09M | |
Mar 2024 | 640K | -66.93M | -10457.81% |
Sep 2025 | 9.36M | -66.47M | -709.57% |
---|---|---|---|
Oct 2025 | 910.6K | -75.75M | -8319.67% |
Dec 2025 | 4.57M | -76.48M | -1672.76% |
Mar 2026 | 5M | -76.62M | -1532.53% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 293254000 | 39.13M | 13.35% |
---|---|---|---|
Sep 2023 | 641537000 | 93.78M | 14.62% |
Dec 2023 | 635353000 | 96.24M | 15.15% |
Mar 2024 | 978153000 | 103.22M | 10.55% |
Jun 2023 | -45.73M | 31.43M | 12.65M |
---|---|---|---|
Sep 2023 | -41.33M | -193.29M | 337.87M |
Dec 2023 | -38.51M | -87.30M | 37.92M |
Mar 2024 | -52.85M | 309K | 393.57M |
Crinetics Pharmaceuticals alternative data
Aug 2023 | 210 |
---|---|
Sep 2023 | 210 |
Oct 2023 | 210 |
Nov 2023 | 210 |
Dec 2023 | 210 |
Jan 2024 | 210 |
Feb 2024 | 210 |
Mar 2024 | 290 |
Apr 2024 | 290 |
May 2024 | 290 |
Jun 2024 | 290 |
Jul 2024 | 290 |
Crinetics Pharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 30375 |
Mar 2024 | 0 | 119390 |
Apr 2024 | 0 | 55326 |
May 2024 | 0 | 113448 |
Jun 2024 | 0 | 63585 |
Jul 2024 | 0 | 106431 |
Aug 2024 | 0 | 6000 |
Sep 2024 | 0 | 26035 |
Oct 2024 | 0 | 14375 |
Nov 2024 | 0 | 501 |
Dec 2024 | 0 | 10000 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | BETZ STEPHEN F. officer: Chief Scientific Officer | Stock Option (Right to Buy) | 2,331 | $1.91 | $4,452 | ||
Option | BETZ STEPHEN F. officer: Chief Scientific Officer | Common Stock | 2,331 | $1.91 | $4,452 | ||
Sale | STRUTHERS RICHARD SCOTT director, officer: President & .. | Common Stock | 10,000 | $57.57 | $575,700 | ||
Sale | KNIGHT JEFF E. officer: Chief Operating Officer | Common Stock | 501 | $56.52 | $28,317 | ||
Option | PIZZUTI DANA officer: Chief Med and Dev Offi.. | Stock option (Right to Buy) | 14,375 | $16.89 | $242,794 | ||
Option | PIZZUTI DANA officer: Chief Med and Dev Offi.. | Common Stock | 14,375 | $16.89 | $242,794 | ||
Sale | PIZZUTI DANA officer: Chief Med and Dev Offi.. | Common Stock | 14,375 | $54.63 | $785,306 | ||
Option | WILSON MARC officer: CFO | Common Stock | 25,000 | $15.29 | $382,250 | ||
Option | WILSON MARC officer: CFO | Common Stock | 25,000 | $15.29 | $382,250 | ||
Sale | WILSON MARC officer: CFO | Common Stock | 25,000 | $51.11 | $1,277,750 |
Patent |
---|
Application Filling date: 15 Jul 2020 Issue date: 25 Aug 2022 |
Application Filling date: 16 Feb 2022 Issue date: 18 Aug 2022 |
Application Filling date: 25 Jan 2022 Issue date: 12 May 2022 |
Application Filling date: 21 Jan 2022 Issue date: 12 May 2022 |
Application Filling date: 7 Sep 2021 Issue date: 10 Mar 2022 |
Grant Filling date: 7 Sep 2021 Issue date: 8 Mar 2022 |
Application Filling date: 26 Oct 2021 Issue date: 17 Feb 2022 |
Grant Filling date: 19 May 2020 Issue date: 30 Nov 2021 |
Application Filling date: 8 Feb 2021 Issue date: 5 Aug 2021 |
Grant Filling date: 16 Sep 2019 Issue date: 27 Jul 2021 |
Quarter | Transcript |
---|---|
Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q4 2020 30 Mar 2021 | Q4 2020 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. R. Scott Struthers (1962) Founder, Pres, Chief Executive Officer & Director | $820,330 |
Dr. Ajay Madan DABT, Ph.D., D.A.B.T. (1968) Chief Devel. Officer | $567,530 |
Mr. Marc J. C. Wilson (1979) Chief Financial Officer & Sec. | $527,720 |
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
Crinetics Pharmaceuticals: Some Caution Warranted
Crinetics Pharmaceuticals: Creating Next-Generation Treatments In Acromegaly
Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO
Crinetics Pharmaceuticals And Its Value Proposition In Acromegaly
Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress
-
What's the price of Crinetics Pharmaceuticals stock today?
One share of Crinetics Pharmaceuticals stock can currently be purchased for approximately $30.24.
-
When is Crinetics Pharmaceuticals's next earnings date?
Unfortunately, Crinetics Pharmaceuticals's (CRNX) next earnings date is currently unknown.
-
Does Crinetics Pharmaceuticals pay dividends?
No, Crinetics Pharmaceuticals does not pay dividends.
-
How much money does Crinetics Pharmaceuticals make?
Crinetics Pharmaceuticals has a market capitalization of 4.90B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 15.28% to 4.01M US dollars.
-
What is Crinetics Pharmaceuticals's stock symbol?
Crinetics Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CRNX".
-
What is Crinetics Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Crinetics Pharmaceuticals?
Shares of Crinetics Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Crinetics Pharmaceuticals's key executives?
Crinetics Pharmaceuticals's management team includes the following people:
- Dr. R. Scott Struthers Founder, Pres, Chief Executive Officer & Director(age: 63, pay: $820,330)
- Dr. Ajay Madan DABT, Ph.D., D.A.B.T. Chief Devel. Officer(age: 57, pay: $567,530)
- Mr. Marc J. C. Wilson Chief Financial Officer & Sec.(age: 46, pay: $527,720)
-
Is Crinetics Pharmaceuticals founder-led company?
Yes, Crinetics Pharmaceuticals is a company led by its founder Dr. R. Scott Struthers.
-
How many employees does Crinetics Pharmaceuticals have?
As Jul 2024, Crinetics Pharmaceuticals employs 290 workers.
-
When Crinetics Pharmaceuticals went public?
Crinetics Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 18 Jul 2018.
-
What is Crinetics Pharmaceuticals's official website?
The official website for Crinetics Pharmaceuticals is crinetics.com.
-
Where are Crinetics Pharmaceuticals's headquarters?
Crinetics Pharmaceuticals is headquartered at Building No. 2, San Diego, CA.
-
How can i contact Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals's mailing address is Building No. 2, San Diego, CA and company can be reached via phone at 858 450 6464.
Crinetics Pharmaceuticals company profile:

Crinetics Pharmaceuticals, Inc.
crinetics.comNASDAQ
290
Biotechnology
Healthcare
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
San Diego, CA 92121
CIK: 0001658247
ISIN: US22663K1079
CUSIP: 22663K107